Cargando…

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma

BACKGROUND: Budesonide/formoterol is an effective treatment for both asthma and chronic obstructive pulmonary disease. This study compared the efficacy and safety of a novel hydrofluoroalkane (HFA) pressurised metered-dose inhaler (pMDI) formulation of budesonide/formoterol with that of budesonide p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morice, A H, Peterson, S, Beckman, O, Osmanliev, D
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2007
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228375/ https://www.ncbi.nlm.nih.gov/pubmed/17887990 http://dx.doi.org/10.1111/j.1742-1241.2007.01574.x

Ejemplares similares

Development of Room Temperature Stable Formulation of Formoterol Fumarate/Beclomethasone HFA pMDI
por: Purohit, D., et al.
Publicado: (2009)

The Impact of Budesonide/Formoterol pMDI Medication Reminders on Adherence in Chronic Obstructive Pulmonary Disease (COPD) Patients: Results of a Randomized, Phase 4, Clinical Study
por: Criner, Gerard J, et al.
Publicado: (2021)

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study
por: Ferguson, Gary T., et al.
Publicado: (2018)

Ammonium Lignosulfonate Adhesives for Particleboards with pMDI and Furfuryl Alcohol as Crosslinkers
por: Hemmilä, Venla, et al.
Publicado: (2019)

Protocol: Influence of Budesonide and Budesonide/Formoterol on Asthma Control in Smoking Asthmatic Adults
por: Boulet, Louis-Philippe, et al.
Publicado: (2010)

Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults
por: Maes, Andrea, et al.
Publicado: (2018)

High strength extrafine pMDI beclometasone/formoterol (200/6 μg) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids
por: Paggiaro, Pierluigi, et al.
Publicado: (2016)

Comparison of Aerosol Formulations of Formoterol Fumarate and Budesonide
por: Nirale, N. M., et al.
Publicado: (2011)

A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Improved Wood-Bond Strengths Using Soy and Canola Flours with pMDI and PAE
por: Barzegar, Mahsa, et al.
Publicado: (2022)

Comparative Efficacy of Budesonide/Formoterol with Budesonide, Formoterol or Placebo for Stable Chronic Obstructive Pulmonary Disease: A Meta-Analysis
por: Tang, Bin, et al.
Publicado: (2019)

Correction to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler(®) to Budesonide/Formoterol Easyhaler(®)
por: Syk, Jörgen, et al.
Publicado: (2019)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations
por: Kuna, P, et al.
Publicado: (2007)

Effect of adjusting the combination of budesonide/formoterol on the alleviation of asthma symptoms
por: Souma, Ryosuke, et al.
Publicado: (2018)

Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study
por: Samajdar, Shambo Samrat, et al.
Publicado: (2023)

A randomized, double-blinded, double-dummy efficacy and safety study of budesonide–formoterol Spiromax® compared to budesonide–formoterol Turbuhaler® in adults and adolescents with persistent asthma
por: Virchow, J. Christian, et al.
Publicado: (2016)

Properties of Eco-Friendly Particleboards Bonded with Lignosulfonate-Urea-Formaldehyde Adhesives and pMDI as a Crosslinker
por: Bekhta, Pavlo, et al.
Publicado: (2021)

Perspective on the Budgetary Impact of FP/FORM pMDI on Treatment and Management of Exacerbation in Moderate-to-Severe Asthma Patients in Singapore
por: Boisseau, Sebastien, et al.
Publicado: (2020)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Tolerability of budesonide/formoterol in patients of Kazakhstan rural regions
por: Nurpeissov, Tair, et al.
Publicado: (2015)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol
por: Bateman, ED, et al.
Publicado: (2006)

Bronchodilatory effect of inhaled budesonide/formoterol and budesonide/salbutamol in acute asthma: a double-blind, randomized controlled trial
por: Arun, Jenish J, et al.
Publicado: (2012)

Potential of Brewer’s Spent Grain as a Potential Replacement of Wood in pMDI, UF or MUF Bonded Particleboard
por: Barbu, Marius Cătălin, et al.
Publicado: (2021)

Long-term maintenance of pediatric asthma: focus on budesonide/formoterol inhalation aerosol
por: Huynh, Peter N, et al.
Publicado: (2010)

Long-term safety of budesonide/formoterol for the treatment of elderly patients with bronchial asthma
por: KAGOHASHI, KATSUNORI, et al.
Publicado: (2014)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study
por: Jones, Rupert, et al.
Publicado: (2017)

Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study
por: Price, David B., et al.
Publicado: (2018)

Water Uptake by Evaporating pMDI Aerosol Prior to Inhalation Affects Both Regional and Total Deposition in the Respiratory System
por: Legh-Land, Victoria, et al.
Publicado: (2021)

Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction
por: Lazarinis, Nikolaos, et al.
Publicado: (2014)

Exposure-Response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients
por: Back, Hyun-moon, et al.
Publicado: (2020)

Budesonide and formoterol effects on rhinovirus replication and epithelial cell cytokine responses
por: Bochkov, Yury A, et al.
Publicado: (2013)

The rapid effects of budesonide plus formoterol in patients with obstructive airway diseases
por: Bayiz, Hulya, et al.
Publicado: (2015)

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016)

Risks of budesonide/formoterol for the treatment of stable COPD: a meta-analysis
por: Tang, Bin, et al.
Publicado: (2019)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

ATTACHED, DETACHED and WITHOUT inhaler technique coaching tools to optimize pMDI use competence, asthma control and quality-of-life in asthmatic adults
por: Ammari, Wesam G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_srtac2pe1gh05p0rifh718663r